Study Identifies Phenotypic Age as Superior Predictor of COPD Mortality Over Chronological Age

A retrospective cohort study of 19,882 patients demonstrates that Phenotypic Age consistently outperforms both chronological age and Klemera-Doubal Method biological age in predicting long-term all-cause mortality in COPD, providing a more precise clinical tool for individualized risk stratification.

Researchers from Xiangya Hospital of Central South University published a retrospective cohort study using data from 19,882 COPD patients enrolled in the UK Biobank between 2006 and 2010.

The study compared the prognostic accuracy of Phenotypic Age (PhenoAge) against chronological age and Klemera-Doubal Method biological age (KDM-BA) over a median follow-up period of 15.8 years, during which 15.1% of the cohort died.

Time-dependent ROC analyses showed that PhenoAge consistently outperformed chronological age, PhenoAge acceleration, and KDM-BA in predicting all-cause mortality at 5-year, 10-year, and 15-year follow-ups.

Specifically, the 5-year AUC for PhenoAge was 0.716 (0.695–0.737) compared to 0.634 (0.612–0.655) for chronological age and 0.644 (0.621–0.666) for KDM-BA.

The integration of PhenoAge into multivariate Cox proportional hazards models yielded a net reclassification index (NRI) of 0.107 and an integrated discrimination improvement (IDI) of 0.010 compared to models based on chronological age.

COPD is increasingly characterized as a pathology of accelerated lung aging, driven by biological mechanisms including cellular senescence, telomere attrition, and chronic systemic inflammation.

The study demonstrates that chronological age does not accurately reflect an individual's biological aging status or their physiological reserve in the context of chronic disease.

Calculating PhenoAge relies on nine routinely measured, clinical-chemistry laboratory biomarkers (including albumin, glucose, C-reactive protein, and white blood cell count), making it an accessible, low-cost tool for clinical settings compared to high-cost genetic or epigenetic tests.

The demonstrated predictive utility of PhenoAge over KDM-BA suggests that simpler clinical chemistry-based algorithms may gain wider clinical and commercial adoption than physiological measurement frameworks.

For drug developers targeting age-related respiratory decline, biological age metrics like PhenoAge could serve as cost-effective patient enrichment tools to stratify participants by baseline biological aging rate in clinical trials.

Further external validation of PhenoAge-based mortality models in independent patient cohorts, particularly those containing a higher proportion of severe and very severe COPD cases, as over 90% of the UK Biobank cohort analyzed had mild-to-moderate disease.